Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

​ Conditions: Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors; Metastatic Castration-resistant Prostate Cancer (mCRPC)

Interventions: Drug: ERW316; Drug: Fulvestrant; Drug: Letrozole

Sponsors: Novartis Pharmaceuticals

Not yet recruiting Conditions: Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors; Metastatic Castration-resistant Prostate Cancer (mCRPC)
Interventions: Drug: ERW316; Drug: Fulvestrant; Drug: Letrozole
Sponsors: Novartis Pharmaceuticals
Not yet recruiting